0000000000428301

AUTHOR

Frédéric Pinguet

showing 1 related works from this author

A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitab…

2013

e13519 Background: For fluoropyrimidines, and especially cap, Health Authorities point out that DPD deficiency confers a significant risk of major toxicity (tox). Identification of at-risk pts is thus relevant. This multicentric prospective study of the French GPCO group (Groupe de Pharmacologie Clinique Oncologique, Unicancer) evaluated the sensitivity, specificity and predictive values of DPD phenotyping and genotyping for predicting severe cap-related tox in metastatic breast cancer pts. Methods: 303 pts were included (15 institutions), 88% received cap as monotherapy, 28% were treated as first line (mean dose at 1st cycle 1957 mg/m2/d). Pre-treatment dihydrouracil (UH2) and uracil (U) …

Cancer Researchmedicine.medical_specialtymacromolecular substances030226 pharmacology & pharmacyGastroenterology[SPI.AUTO]Engineering Sciences [physics]/AutomaticCapecitabine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerInternal medicine[ SPI.AUTO ] Engineering Sciences [physics]/AutomaticmedicineDihydropyrimidine dehydrogenaseProspective cohort studybusiness.industryDihydrouracilmedicine.diseaseMetastatic breast cancer3. Good healthSurgery[SPI.AUTO] Engineering Sciences [physics]/AutomaticOncologychemistry030220 oncology & carcinogenesisRelative riskToxicitybacteriaPublished in Journal of Clinical Oncology vol. 31 : 2013 (Suppl ;abstr e13519)businessmedicine.drug
researchProduct